Want to see SE:S2M full AI Analyst Report?
S2M Stock Chart & Stats
kr0.01
<kr0.01(4.00%)
At close: 4:00 PM EDT
kr0.01
<kr0.01(4.00%)
Day’s Range― - ―
52-Week Range<kr0.01 - kr0.03
Previous CloseN/A
Volume3.03M
Average Volume (3M)2.90M
Market Cap
kr5.62M
Enterprise Valuekr8.39
Total Cash (Recent Filing)kr906.87K
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding898,657,040
10 Day Avg. Volume1,954,268
30 Day Avg. Volume2,901,877
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.93
Price to Sales (P/S)0.64
P/FCF Ratio-6.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr60.00M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA near-zero debt load materially reduces financial risk and interest burdens, providing durable flexibility to absorb operating swings, fund targeted R&D or working capital, and prioritize strategic initiatives without short-term refinancing pressure.
Improving Operating Cash FlowTransition from multi-year cash burn to positive operating cash flow shows the business can generate core cash. This improvement supports near-term liquidity and gives management runway to pursue margins and operational fixes over the coming months.
Demonstrated Profitability In 2024A prior year of healthy gross and net profitability indicates the underlying business model can reach sustainable margins at scale; this provides a realistic path back to profitability if revenue trends and cost discipline are restored.
Bears Say
High Earnings VolatilityMarked swings between profit and deep losses weaken predictability of cash flows and capital planning. For a small medical-instruments firm, this volatility makes budgeting, supplier commitments, and longer-term investments riskier over the next several quarters.
Sharp Revenue Decline In 2025A ~22% revenue drop and negative gross profit signal structural demand or execution issues that directly impair margin sustainability and operating leverage. Recovering top-line growth is critical to restore durable profitability and cash generation.
Weak Free Cash Flow ConversionNear-zero free cash flow despite positive operating cash flow indicates poor conversion to discretionary cash after capex and working capital. This constrains reinvestment, reduces buffer for shocks, and may force external funding if negative trends persist.
S2M FAQ
What was S2Medical AB Class B’s price range in the past 12 months?
S2Medical AB Class B lowest stock price was <kr0.01 and its highest was kr0.03 in the past 12 months.
What is S2Medical AB Class B’s market cap?
S2Medical AB Class B’s market cap is kr5.62M.
When is S2Medical AB Class B’s upcoming earnings report date?
S2Medical AB Class B’s upcoming earnings report date is Aug 21, 2026 which is in 10 days.
How were S2Medical AB Class B’s earnings last quarter?
S2Medical AB Class B released its earnings results on Feb 20, 2026. The company reported -kr0.012 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is S2Medical AB Class B overvalued?
According to Wall Street analysts S2Medical AB Class B’s price is currently Overvalued.
Does S2Medical AB Class B pay dividends?
S2Medical AB Class B does not currently pay dividends.
What is S2Medical AB Class B’s EPS estimate?
S2Medical AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does S2Medical AB Class B have?
S2Medical AB Class B has 898,657,040 shares outstanding.
What happened to S2Medical AB Class B’s price movement after its last earnings report?
S2Medical AB Class B reported an EPS of -kr0.012 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.692%.
Which hedge fund is a major shareholder of S2Medical AB Class B?
Currently, no hedge funds are holding shares in SE:S2M
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
S2Medical AB Class B
S2Medical AB (publ) focuses on the development, production, and commercialization of advanced wound care solutions, specifically targeting burns and chronic wounds. Their product range features INSTAQRETT, a sterile, disposable tool for mechanical debridement; EPIPROTECT SafeStop, designed to control bleeding; and Instagraft, a single-use medical device for treating complex and prolonged wounds. The company also supplies EPIPROTECT tissue replacement products and INSTABIND-branded bandages, which are known for being washable, waterproof, and self-adhesive. Furthermore, S2Medical distributes Silverlon dressings, which facilitate the delivery of silver ions to the wound. In addition to its product offerings, the company operates specialized wound healing centers known as S2Clinic. Founded in 2013, S2Medical is headquartered in Linköping, Sweden.